CocoaVia Dark Chocolate Bars Shown To Lower Cholesterol
The results of a University of Illinois study have demonstrated an effective way to lower cholesterol levels - by eating chocolate bars."Eating two CocoaVia dark chocolate bars a day not only lowered cholesterol, it had the unexpected effect of also lowering systolic blood pressure, " said John Erdman, a U.
Physicians And Patients Nationwide Discuss Controversial Results Of Recent Cholesterol Lowering Study
Sermo (http://www.sermo.com), the largest physician-only online community, today announced the results of a physician survey prompted by the swirl of media coverage following the release of ENHANCE trial data at the recent American College of Cardiology (ACC) conference.
Sorting Of CEA Modulated By Cholesterol, Implications For Inflammatory Bowel Disease
In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface. Interestingly, polarity was not significantly affected by this approach.
Cholesterol, Blood Pressure Control May Reverse Atherosclerosis In Adults With Diabetes
Aggressively lowering cholesterol and blood pressure levels below current targets in adults with type 2 diabetes may help to prevent - and possibly reverse - hardening of the arteries, according to new research supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
eFoodSafety Launches Cinnechol TM , An All-Natural Alternative To Conventional Cholesterol Drugs
eFoodSafety.com (OTCBB: EFSF, http://www.efoodsafety.com), a researcher, developer, and marketer of whole food nutraceutical products, has launched an all-natural supplement, called Cinnechol™ (http://www.cinnechol.com), that offers a complementary and/or alternative solution to traditional cholesterol drugs.
Merck Receives Not Approvable Letter From FDA For MK-0524A ER Niacin laropiprant
Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia.
Effects Of Rimonabant On Cardiometabolic Risk Profile Include Loss Of Visceral Fat And Mobilization Of Liver Fat
At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.
High Cholesterol In Your 40s Increases Risk Of Alzheimer's Disease
People with high cholesterol in their early 40s are more likely to develop Alzheimer's disease than those with low cholesterol, according to research that will be presented at the upcoming American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for 'Tredaptive'™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company's Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect.